- Stocks
- Pharma & Healthcare
- IPCA Laboratories
IPCA Laboratories share price
NSE: IPCALABPharma & HealthcareDrug Manufacturers - Specialty & Generic
IPCA Laboratories at a glance
IPCA Laboratories (NSE: IPCALAB) closed at ₹1,932.90 on 22 Oct 2026, up 0.62% on the day. With a market capitalisation of ₹48,293 Cr, it ranks 195th by market cap among the 4,183 NSE companies Pivot tracks (a mid-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Drug Manufacturers - Specialty & Generic.
At its last close the stock traded at 43× trailing earnings, against a return on equity of 14.2% in FY26. Over the past year the share price has risen 48.4%. Its 52-week range is ₹1,251.60 (24 Oct 2025) to ₹2,038.00 (18 Sep 2026); the last close is 5.2% below the high. In Q4 FY26, the quarter ended 31 Mar 2026, revenue was ₹2,388 Cr (+6.3% year on year) and net profit ₹309 Cr (+370.4%), on a consolidated basis. Promoters held 44.72% of the company as of 30 Jun 2026.
Key numbers
- Market cap
- ₹48,293 CrRank 195 on NSE
- P/E (trailing)
- 43×
- Price to book
- 5.04×FY26
- EPS (TTM)
- ₹46.94to Q4 FY26
- ROE
- 14.2%FY26
- ROCE
- 17.2%FY26
- Debt to equity
- 0.09FY26
- Net profit margin
- 12.4%FY26
- Book value / share
- ₹317.85FY26
- Dividend payout
- 4.4%FY26
- 52-week high
- ₹2,038.0018 Sep 2026
- 52-week low
- ₹1,251.6024 Oct 2025
- 1-year return
- +48.4%
- RSI (14-day)
- 52.5
Returns to 22 Oct 2026
| Period | 1 day | 1 week | 1 month | 3 months | 1 year |
|---|---|---|---|---|---|
| Price change | +0.62% | +0.6% | −3.4% | +7.9% | +48.4% |
IPCA Laboratories quarterly results
| Quarter | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹2,093 Cr | ₹2,355 Cr | ₹2,245 Cr | ₹2,247 Cr | ₹2,309 Cr | ₹2,557 Cr | ₹2,393 Cr | ₹2,388 Cr |
| Revenue YoY | +31.8% | +15.8% | +9.4% | +10.5% | +10.3% | +8.6% | +6.6% | +6.3% |
| Net profit | ₹199 Cr | ₹245 Cr | ₹277 Cr | ₹66 Cr | ₹234 Cr | ₹284 Cr | ₹364 Cr | ₹309 Cr |
| Net profit YoY | +19.7% | +78.6% | +24.6% | +2,160.5% | +17.8% | +15.5% | +31.3% | +370.4% |
| Net margin | 9.5% | 10.4% | 12.4% | 2.9% | 10.2% | 11.1% | 15.2% | 13.0% |
| EPS | ₹7.58 | ₹9.05 | ₹9.78 | ₹2.67 | ₹9.19 | ₹12.35 | ₹12.09 | ₹13.31 |
IPCA Laboratories financials
| Item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| Revenue | ₹5,420 Cr | ₹5,830 Cr | ₹6,244 Cr | ₹7,705 Cr | ₹8,940 Cr | — |
| Operating profit | ₹1,389 Cr | ₹1,136 Cr | ₹745 Cr | ₹950 Cr | ₹1,336 Cr | — |
| Net profit | ₹1,149 Cr | ₹911 Cr | ₹492 Cr | ₹529 Cr | ₹788 Cr | — |
| EPS (₹) | ₹45.00 | ₹35.00 | ₹19.00 | ₹26.00 | ₹35.00 | — |
| Cash from operations | ₹1,090 Cr | ₹856 Cr | ₹806 Cr | ₹945 Cr | ₹1,321 Cr | — |
| Total debt | ₹9 Cr | ₹395 Cr | ₹652 Cr | ₹580 Cr | ₹543 Cr | ₹109 Cr |
| Shareholders' equity | ₹4,702 Cr | ₹5,492 Cr | ₹5,842 Cr | ₹6,332 Cr | ₹6,948 Cr | ₹8,064 Cr |
IPCA Laboratories shareholding pattern
| Holder | 31 Mar 2025 | 30 Jun 2025 | 30 Sep 2025 | 31 Dec 2025 | 31 Mar 2026 | 30 Jun 2026 |
|---|---|---|---|---|---|---|
| Promoters | 44.72% | 44.72% | 44.72% | 44.72% | 44.72% | 44.72% |
| Foreign institutions | 10.76% | 10.67% | 10.43% | 10.63% | 10.63% | 10.73% |
| Domestic institutions | 36.06% | 36.20% | 36.77% | 37.32% | 37.45% | 37.37% |
| Non-institutions | 8.46% | 8.41% | 8.07% | 7.33% | 7.20% | 7.18% |
IPCA Laboratories vs peers
The listed Pharma & Healthcare companies nearest to IPCA Laboratories by market capitalisation.
| Company | Price | 1 day | 1 year | Market cap | P/E | ROE |
|---|---|---|---|---|---|---|
| ASTERDMAster DM Health | ₹647.20 | −0.46% | −5.5% | ₹57,068 Cr | 101.1 | 8.5% |
| FORTISFortis Healthcare | ₹720.15 | −0.67% | −33.5% | ₹54,859 Cr | 52.3 | 10.5% |
| ABBOTINDIAAbbott India | ₹25,445.00 | −1.57% | −15.3% | ₹53,888 Cr | 34.8 | 33.4% |
| BIOCONBiocon | ₹332.85 | −0.19% | −5.1% | ₹53,829 Cr | 117.6 | 1.1% |
| IPCALABIPCA Laboratories | ₹1,932.90 | +0.62% | +48.4% | ₹48,293 Cr | 43 | 14.2% |
| GLANDGland Pharma | ₹2,910.60 | −0.66% | +52.0% | ₹47,020 Cr | 46.7 | 9.9% |
| ANTHEMAnthem Biosciences | ₹802.40 | −0.52% | +3.0% | ₹45,113 Cr | 76.6 | 19.4% |
Ask anything about IPCA Laboratories
Pivot answers on the live chart with evidence you can check, and tests strategies against IPCALAB's own history. Try: “Why has IPCALAB moved over the last three months?” · “Backtest a 50-day moving-average crossover on IPCALAB over five years” · “Compare IPCALAB with ASTERDM on margins and valuation”
Frequently asked questions about IPCA Laboratories
What is the share price of IPCA Laboratories today?
IPCA Laboratories (NSE: IPCALAB) last closed at ₹1,932.90 on 22 Oct 2026. Its 52-week high is ₹2,038.00 and its 52-week low is ₹1,251.60.
What is the market cap of IPCA Laboratories?
IPCA Laboratories' market capitalisation is ₹48,293 Cr (₹48,293 Cr) at the 22 Oct 2026 close, ranking 195th among the NSE companies Pivot tracks.
What is the P/E ratio of IPCA Laboratories?
IPCA Laboratories trades at a trailing P/E of 43. The median P/E of the 6 closest Pharma & Healthcare peers by market cap is 76.6.
What is the ROE and ROCE of IPCA Laboratories?
Return on equity was 14.2% in FY26 and return on capital employed was 17.2% in FY26 (consolidated figures).
Is IPCA Laboratories a debt-free company?
No. IPCA Laboratories' debt-to-equity ratio was 0.09 in FY26, with total debt of ₹109 Cr.
What were IPCA Laboratories' latest quarterly results?
For Q4 FY26 (quarter ended 31 Mar 2026), IPCA Laboratories reported revenue of ₹2,388 Cr, +6.3% year on year, and net profit of ₹309 Cr, +370.4% year on year.
How has IPCA Laboratories stock performed over the last year?
IPCA Laboratories' share price has risen 48.4% over the past year, +7.9% over three months and −3.4% over one month, to the 22 Oct 2026 close.
What is the shareholding pattern of IPCA Laboratories?
As of 30 Jun 2026: promoters 44.72%, foreign institutions 10.73%, domestic institutions 37.37%, non-institutions 7.18%.
Who are IPCA Laboratories' competitors?
The listed Pharma & Healthcare companies closest to IPCA Laboratories by market cap are Aster DM Health, Fortis Healthcare, Abbott India, Biocon, Gland Pharma and Anthem Biosciences.
Is IPCA Laboratories a good stock to buy?
Pivot does not give buy or sell recommendations. This page sets out IPCA Laboratories' price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on IPCALAB against its own history before risking money. This is analysis, not financial advice.
Sources and method
Prices: NSE daily closes to 22 Oct 2026 (returns and ratios at the 22 Oct 2026 close). Fundamentals: company filings via Moneycontrol, consolidated where available. Shareholding: exchange shareholding-pattern filings. The 52-week range uses intraday highs and lows; the chart marks closing prices. P/E is the last close over trailing twelve-month EPS. Market-cap rank is among the 4,183 NSE companies Pivot tracks; SEBI's bands call the top 100 large-cap and the next 150 mid-cap. Figures marked “—” are not available rather than zero. This is analysis, not financial advice.
More: all Pharma & Healthcare stocks · companies starting with I · all NSE stocks · this page as text